Krebiozen Research Foundation v. Beacon Press, Inc.

134 N.E.2d 1, 334 Mass. 86, 1956 Mass. LEXIS 621
CourtMassachusetts Supreme Judicial Court
DecidedMay 3, 1956
StatusPublished
Cited by44 cases

This text of 134 N.E.2d 1 (Krebiozen Research Foundation v. Beacon Press, Inc.) is published on Counsel Stack Legal Research, covering Massachusetts Supreme Judicial Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Krebiozen Research Foundation v. Beacon Press, Inc., 134 N.E.2d 1, 334 Mass. 86, 1956 Mass. LEXIS 621 (Mass. 1956).

Opinion

Whittemore, J.

The plaintiffs seek to enjoin publication and distribution by the defendant of a book allegedly entitled either “ 'Krebiozen’: The Great Cancer Mystery,” or “The Great Cancer Mystery,” by George D. Stoddard. This is the plaintiffs’ appeal from the interlocutory decree *87 sustaining the defendant’s demurrer and from the final decree dismissing the bill of complaint. There was no error.

The plaintiff Krebiozen Research Foundation is identified in the bill as an Illinois nonprofit corporation. The plaintiff Andrew C. Ivy is described as a medical doctor and physiologist, head of the department of clinical science at the University of Illinois, who has been engaged “for over five years in research and clinical investigation of said drug in his capacity as scientific advisor of said Krebiozen Research Foundation.” The plaintiffs Marko Durovic and Stevan Durovic are stated to be the proprietors of Duga Laboratories which owns the manufacturing rights to produce Krebiozen. The bill states, “Dr. Durovic is a medical doctor who developed said drug, Krebiozen. He has worked with Dr. Ivy in research and investigation to determine the efficacy of said drug in the treatment of cancer.” Included quotations from the subject book indicate that the reference is to Stevan Durovic.

The defendant is described as a Massachusetts business corporation, the publisher of the subject book, which publishes and distributes books widely for sale throughout the United States. It is alleged that galley proofs of the book have already been published and distributed and that the book is about to be put on general public sale.

The bill states that “Being a drug in the experimental stage, Krebiozen’s therapeutic merits have yet to be conclusively established in the United States.”

It is alleged also that “Dr. Ivy and Dr. Durovic have performed a thorough, painstaking, basic research on the drug involving the use of many animals and hundreds of case reports supplied by physicians of cancer patients throughout the United States. (See Exhibit ‘A.’)” The reference is to a thirty page booklet attached to the bill of complaint entitled “Report on Krebiozen. An agent for the treatment of cancer. Its clinical pharmacodynamie and chemical properties 1951-1954. By the Krebiozen Research Foundation.” Twenty-three pages of print in the exhibit are summaries of what one hundred doctors are stated to *88 have said about approximately one hundred twenty-five patients, each doctor and patient being identified by initials.

The bill recites that the plaintiffs believe and allege the book “to contain false, fraudulent, wrongful, malicious and erroneous statements which tend to injure and destroy the good name and professional reputation of the . . . [plaintiffs] and the commercial value of the drug, Krebiozen.” It also alleges that certain specified statements 1 and other statements and the whole tenor of the book “expressly or impliedly state that the . . . [plaintiffs] are trying to promote a secret remedy without adequate scientific research and that . . . [the plaintiffs] know their remedy to be worthless . . ., [and] are designed and will have the effect of impeding further clinical investigation of said drug and its commercial marketability in foreign countries where its sale is licensed.” The bill specifies that the statements quoted in the bill and other statements and the whole tenor of the book libel Dr. Durovic and Dr. Ivy in charging them with having acted unethically and violated professional standards, with using testimonials from patients contrary to professional standards, with the promotion of secret remedies for personal profits, with shoddy and careless re *89 search, and with uncritical indorsement of remedies. It also alleges that the publication of the book will cause irreparable damage to the professional reputations of the plaintiffs as doctors and scientists, and will subject them to professional suspicion, contempt and "ostracization” and to public contempt and ridicule, and that the trade name of the drug will be irreparably injured.

The specifications of the bill indicate that in some respects the statements in the book do not warrant the general allegations made about it. For example, the bill makes the point that the author of the book knows that the suggestions of nonprofessional reliance on paid testimonials from patients are false. But the relevant quoted words are, "There must have been considerable expense also in gathering testimonials from cancer patients” and "... subjective testimonials [were] their chief evidence.” These words do not charge that any payments were made to patients. There would presumably be expense in getting the medicine out to doctors for testing and getting back and collating reports, and for aught that appears that is the expense referred to. The one hundred twenty-five or so reports in exhibit A show that the plaintiffs were making use of favorable reports from doctors about patients, and were, presenting this part of the available data much in the way testimonial material direct from patients is often presented by those who sell medicines with the use of testimonials. The contents of these reports, to some extent at least, reflect subjective aspects of the reported illnesses.

And while it is questionable how far the defendant’s motivation will be of controlling significance in a case of a writing in a field of public interest (see Near v. Minnesota, 283 U. S. 697, and footnote, page 97, post), it is to be noted that the bill here does not make out a case of active malice in the defendant — of a purpose to injure the plaintiffs or their business rather than an intent to publish a book about a controversial subject.

The summary allegation that the false statements are “malicious” is usual in a libel suit. The word is one of art *90 in such pleading and does not carry the import of “actual malice” (Commonwealth v. Bonner, 9 Met. 410; Kenney v. McLaughlin, 5 Gray, 3, 5; Goodwin v. Daniels, 7 Allen, 61, 63; Conner v. Standard Publishing Co. 183 Mass. 474, 480; and see G. L. [Ter. Ed.] c. 231, § 92). The word “fraudulent” without specification does not advance the pleader (Garst v. Hall & Lyon Co. 179 Mass. 588; Nye v. Storer, 168 Mass. 53; Second Society of Universalists in Boston v. Royal Ins. Co. Ltd. 221 Mass. 518, 523; Cosmopolitan Trust Co. v. S. L. Agoos Tanning Co. 245 Mass. 69, 73). These words are used in the bill in respect of the statements in the book and not as to the defendant’s actions. That the defendant had refused in spite of the plaintiffs’ efforts to let the book be seen (efforts made, as asserted, “to offer proof as to the inaccuracy of certain statements . . . [allegedly] libellous”) is consistent with sound business procedure.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sindi v. El-Moslimany
896 F.3d 1 (First Circuit, 2018)
Organovo Holdings, Inc. v. Dimitrov
162 A.3d 102 (Court of Chancery of Delaware, 2017)
In Re: Conservatorship of Jack Wayne Turner
Court of Appeals of Tennessee, 2014
Clay Corp. v. Colter
30 Mass. L. Rptr. 536 (Massachusetts Superior Court, 2012)
Commonwealth v. Barnes
461 Mass. 644 (Massachusetts Supreme Judicial Court, 2012)
Carr v. Entercom Boston, LLC
23 Mass. L. Rptr. 169 (Massachusetts Superior Court, 2007)
Haddad v. Nordgren Memorial Chapel, Inc.
20 Mass. L. Rptr. 230 (Massachusetts Superior Court, 2005)
Care & Protection of Edith
659 N.E.2d 1174 (Massachusetts Supreme Judicial Court, 1996)
Shawsheen River Estates Associates Ltd. Partnership v. Herman
3 Mass. L. Rptr. 475 (Massachusetts Superior Court, 1995)
Clement v. Sheraton Boston Corp.
1 Mass. L. Rptr. 579 (Massachusetts Superior Court, 1993)
Steven M. Kramer v. Richard Thompson
947 F.2d 666 (Third Circuit, 1991)
Bank of New England, N.A. v. Mortgage Corp. of New England
567 N.E.2d 961 (Massachusetts Appeals Court, 1991)
Leonardini v. Shell Oil Co.
216 Cal. App. 3d 547 (California Court of Appeal, 1989)
Dairy Stores, Inc. v. Sentinel Publishing Co.
516 A.2d 220 (Supreme Court of New Jersey, 1986)
American Grain Products Processing Institute v. Department of Public Health
467 N.E.2d 455 (Massachusetts Supreme Judicial Court, 1984)
AM. GRAIN PROD. PROCESSING INST v. Dept. of Pub. Hlth.
467 N.E.2d 455 (Massachusetts Supreme Judicial Court, 1984)
Nyer v. Munoz-Mendoza
430 N.E.2d 1214 (Massachusetts Supreme Judicial Court, 1982)
Queen v. Tennessee Valley Authority
508 F. Supp. 532 (E.D. Tennessee, 1980)

Cite This Page — Counsel Stack

Bluebook (online)
134 N.E.2d 1, 334 Mass. 86, 1956 Mass. LEXIS 621, Counsel Stack Legal Research, https://law.counselstack.com/opinion/krebiozen-research-foundation-v-beacon-press-inc-mass-1956.